文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

使用紫杉醇涂层器械进行股腘动脉介入治疗的随机对照试验中的死亡率:一项更新的患者水平荟萃分析

Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis.
PubMed 文献 · Lancet · 2023-10-24

该研究纳入10项随机对照试验共2666例受试者,中位随访4.9年,采用患者水平汇总分析评估紫杉醇涂层器械与对照器械的死亡风险。意向性治疗分析(HR 1.14,95%CI 0.93-1.40)及多种接受治疗分析均未观察到死亡显著增加,紫杉醇剂量对死亡风险无显著影响。作者认为该荟萃分析未发现紫杉醇涂层器械暴露与死亡风险相关。

要点

  • 10项随机对照试验、2666例受试者,中位随访4.9年,患者水平汇总分析。
  • 意向性治疗分析HR 1.14(95%CI 0.93-1.40),未观察到死亡显著增加。
  • 紫杉醇剂量对死亡风险无显著影响。

核心结论

  • 该荟萃分析未发现紫杉醇涂层器械暴露与死亡风险相关,为患者、医生和监管机构提供了关于紫杉醇涂层器械安全性的 reassurance。

研究设计与样本

  • 纳入10项比较紫杉醇涂层器械与对照器械的随机对照试验,进行患者水平汇总分析,共2666例受试者,中位随访4.9年。
  • 采用Cox回归模型评估紫杉醇暴露对死亡风险的影响,包括意向性治疗分析(主要分析)和三种接受治疗分析(考虑指数操作时及随时间发生的治疗组交叉)。
  • 同时评估紫杉醇剂量和基线协变量的影响。

主要发现

  • 意向性治疗分析中,紫杉醇涂层器械组与对照器械组相比死亡风险无显著增加(HR 1.14,95%CI 0.93-1.40)。
  • 接受治疗分析中HR 1.13(95%CI 0.92-1.39)。
  • 两种交叉分析中,晚交叉删失时HR 1.07(95%CI 0.87-1.31),从紫杉醇暴露日期起分析交叉时HR 1.04(95%CI 0.84-1.28)。
  • 紫杉醇剂量对死亡风险无显著影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Numerous randomised clinical trials and real-world studies have supported the safety of paclitaxel-coated devices for the treatment of femoropopliteal occlusive disease. However, a 2018 summary-level meta-analysis suggested an increased mortality risk for paclitaxel-coated devices compared with uncoated control devices. This study presents an updated analysis of deaths using the most complete and current data available from pivotal trials of paclitaxel-coated versus control devices. METHODS: Ten trials comparing paclitaxel-coated versus control devices were included in a patient-level pooled analysis. Cox regression models were used to evaluate the effect of paclitaxel exposure on risk of death in both intention-to-treat (ITT; primary analysis) and three as-treated analysis sets accounting for treatment group crossover at the index procedure and over time. The effect of paclitaxel dose and baseline covariates were also evaluated. FINDINGS: A total of 2666 participants were included with a median follow-up of 4·9 years. No significant increase in deaths was observed for patients treated with paclitaxel-coated devices. This was true in the ITT analysis (hazard ratio [HR] 1·14, 95% CI 0·93-1·40), the as-treated analysis (HR 1·13, 95% CI 0·92-1·39), and in two crossover analyses: 1·07 (0·87-1·31) when late crossovers were censored and 1·04 (0·84-1·28) when crossovers were analysed from the date of paclitaxel exposure. There was no significant effect of paclitaxel dose on mortality risk. INTERPRETATION: This meta-analysis found no association between paclitaxel-coated device exposure and risk of death, providing reassurance to patients, physicians, and regulators on the safety of paclitaxel-coated devices. FUNDING: Becton Dickinson, Boston Scientific, Cook, Medtronic, Philips, Surmodics, and TriReme Medical.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Parikh SA, Schneider PA, Mullin CM, et al. Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis. Lancet. 2023. PMID: 37890499. doi:10.1016/S0140-6736(23)02189-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。